UBS AM
ALXO icon

UBS AM’s ALX Oncology ALXO Stock Holding History

UBS AM’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,823
Closed -$132K – 2802
2024
Q2 		$132K Buy
+21,823
New +$268K ﹤0.01% 2770
2023
Q3 		– Sell
-11,581
Closed -$52.3K – 2592
2023
Q2 		$52.3K Hold
11,581
– – ﹤0.01% 2661
2023
Q1 		$52.3K Buy
+11,581
New +$87.7K ﹤0.01% 2661
2022
Q3 		– Sell
-13,251
Closed -$107K – 2740
2022
Q2 		$107K Sell
13,251
-352,402
-96% -$3.84M ﹤0.01% 2643
2022
Q1 		$6.18M Buy
365,653
+13,401
+4% +$229K ﹤0.01% 1265
2021
Q4 		$7.57M Buy
352,252
+79,915
+29% +$3.45M ﹤0.01% 1231
2021
Q3 		$20.1M Sell
272,337
-3,796
-1% -$253K 0.01% 865
2021
Q2 		$15.1M Buy
276,133
+93,273
+51% +$5.58M 0.01% 971
2021
Q1 		$13.5M Buy
182,860
+149,651
+451% +$11.8M 0.01% 981
2020
Q4 		$2.86M Buy
+33,209
New +$2M ﹤0.01% 1540

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM's ALXO Position: Q3 2024 in Review

UBS AM sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 21,823 shares — an estimated $132K sold.

UBS AM first reported a position in ALXO in Q4 2020 and held it in 10 quarters. The position peaked at $20.1M in Q3 2021. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

  • UBS AM reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
  • UBS AM sold 21,823 ALX Oncology shares in Q3 2024, an estimated $132K.
  • UBS AM first reported a position in ALX Oncology in Q4 2020 and held it in 10 quarters.
  • UBS AM's ALX Oncology position peaked at $20.1M in Q3 2021.
  • 92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on UBS AM's 13F filing for Q3 2024, filed 14 Nov 2024.